Brief: Ryvu Therapeutics Says Starts Phase II Study Of RVU120 For Myelofibrosis
05/12/2024 06:03
Dec 5 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* FIRST PATIENT DOSED IN PHASE II STUDY OF RVU120 FOR
MYELOFIBROSIS
* RVU120 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH
RUX
Source text: ID:nEM46JXWla
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project